ClinicalThought

Share

Program Content

Activities

  • FAQs: Refining CLL and SLL Tx
    FAQs: Fine-tuning Contemporary Treatment for Patients With CLL/SLL
    Clinical Thought
    Congratulations: You achieved a completion on 04/09/2022

    Released: July 21, 2023

    Expires: July 20, 2024

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

cover img faculity

Brian T. Hill, MD, PhD

Director, Lymphoid Malignancies Program
Staff Physician, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Provided by

ProCE Banner

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca, BeiGene Ltd, and Lilly. Supported by independent educational grants from Merck & Co., Inc., Rahway, NJ, USA, and Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

AstraZeneca

BeiGene, Ltd.

Janssen Biotech, Inc.

Lilly

Merck Sharp & Dohme Corp.

Pharmacyclics LLC, an AbbVie Company

Partners

Clinical Care Options, LLC

ProCE Banner